You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 6, February 14, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  This Week in JAMA
 This Article
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

This Week in JAMA

JAMA. 2007;297:561.

Glycoprotein Inhibitors in Acute Coronary Syndromes

Among patients with acute coronary syndromes (ACS) who undergo invasive procedures, administration of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors either upstream to all patients or deferred for selective use just prior to angiography is recommended. However, it is not known if one strategy is associated with improved outcomes. Stone and colleagues (SEE ARTICLE) report results of the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Timing Trial, in which patients with moderate- and high-risk ACS who were having early invasive procedures were randomly assigned to receive either routine upstream or deferred selective Gp IIb/IIIa inhibitor therapy. The trial investigators found that deferred selective Gp IIb/IIIa inhibitor therapy was associated with a nonsignificant increase in ischemic events and did not meet the trial criterion for noninferiority. Selective deferred Gp IIb/IIIa use was associated with a lower risk of bleeding events. In an editorial, Mahaffey and Harrington (SEE ARTICLE) discuss aspects of the ACUITY Timing Trial design, the trial outcomes, and potential application to clinical practice.


Figure 70002


Iron Reduction and CVD Outcomes

Several small studies have suggested an association of body iron stores in excess of physiological requirements with an increased risk of cardiovascular disease (CVD). In a multicenter randomized trial of patients with symptomatic peripheral arterial disease, Zacharski and colleagues (SEE ARTICLE) tested the hypothesis that reducing body iron stores—while avoiding iron deficiency—through phlebotomy would be associated with a lower risk of all-cause mortality or a composite outcome of death plus nonfatal myocardial infarction and stroke. The authors found no overall differences in mortality, myocardial infarction, or stroke among patients having phlebotomy vs patients in the control group. In an editorial, Hu (SEE ARTICLE) discusses the largely negative evidence for an association of body iron with cardiovascular disease risk and directions for future investigation.


Assessment of Cardiovascular Risk in Women

Assessment of cardiovascular disease risk often relies on the presence or absence of traditional risk factors (age, hypertension, smoking, diabetes, and hyperlipidemia); however, among women, up to 20% of all coronary events occur in the absence of these major risk factors. In this issue of JAMA, Ridker and colleagues (SEE ARTICLE) describe the development and validation of a global cardiovascular risk algorithm for women, the Reynolds Risk Score. The authors found that the Reynolds Risk Score, which includes traditional and novel risk factors, reclassified 40% to 50% of women who were categorized as having a 10-year intermediate risk of cardiovascular events based on the currently used algorithm into higher or lower risk categories. In an editorial, Blumenthal and colleagues (SEE ARTICLE) discuss the advantages of the new algorithm and the need for models that will predict women's long-term (20 to 30 years) risk of cardiovascular events.


CLINICIAN'S CORNER
Sexual Concerns After Menopause
Clinical Crossroads

Effects of aging and menopause on female sexual response, the evaluation of postmenopausal sexual concerns, and the safety and efficacy of treatment options are discussed in the case of Ms B, a 60-year-old woman who has experienced sexual difficulties since entering menopause.

(SEE ARTICLE)


Medical News & Perspectives

An increased suicide risk in children and adolescents taking antidepressants may extend into young adulthood, but not treating these individuals may also pose risks, according to an FDA panel that advised new warnings for the drugs.

(SEE ARTICLE)


Health Record Access After Death

Legal, ethical, and clinical concerns relating to the disclosure of health information after death.

(SEE ARTICLE)


Author in the Room Teleconference

Join Paul M Ridker, March 21, 2007, from 2 to 3 PM eastern time to discuss an algorithm to assess global cardiovascular risk in women. To register, go to http://www.ihi.org/AuthorintheRoom.


Audio Commentary

Dr DeAngelis summarizes and comments on this week's issue. Go to http://jama.ama-assn.org/misc/audiocommentary.dtl.


JAMA Patient Page

For your patients: Information about sexual concerns after menopause.

(SEE ARTICLE)



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.